First line of the email MUST contain NCT # and Site #
CONTACT
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
Patients have moderate to severe plaque psoriasis
Patients have signed informed consent form (ICF)
You may not be if
Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF
Clareo Health | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
